Company Profile
Lyell Immunopharma Stock Price, News & Analysis
- Ticker:
- LYEL
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Headquartered in the United States and listed on NASDAQ, Lyell Immunopharma is followed within the immunology universe for its exposure to chronic-disease treatment demand and catalyst-driven clinical updates.
Stock performance
12.63 USD (+5.51%)
Close
Last updated: June 23, 2026 at 00:00
294.71M USD
Market cap
Why the stock is moving
LYEL is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Lyell Immunopharma is an immunology-oriented biopharmaceutical company focused on inflammatory and immune-mediated disease programs, where each new data point can reshape expectations for the pipeline and the next catalyst window.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Lyell Immunopharma is followed within the immunology universe for its exposure to chronic-disease treatment demand and catalyst-driven clinical updates.
Business Model Characteristics
Lyell Immunopharma is a pipeline-led immunology story, so the market tends to track readouts, regulatory milestones, and how the company expands from one immune program to the next.
Position Within the Biotechnology Landscape
Compared with more mature peers, Lyell Immunopharma sits close to the development side of the biotech landscape, where immunology data can change sentiment quickly.
Future catalysts
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Source: Lyell Immunopharma
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Lyell Immunopharma (LYEL)?
Lyell Immunopharma (LYEL) most recently closed at 12.63 USD, a +5.51% move versus the previous session.
What is the market cap of Lyell Immunopharma (LYEL)?
Lyell Immunopharma currently has a market capitalization of 294.71M USD on BioPharmSignal.
What does Lyell Immunopharma do?
Lyell Immunopharma is an immunology-oriented biopharmaceutical company focused on inflammatory and immune-mediated disease programs, where each new data point can reshape expectations for the pipeline and the next catalyst window.
On which exchange is LYEL stock listed?
Lyell Immunopharma (LYEL) is associated with NASDAQ, Headquartered in the United States and listed on NASDAQ, Lyell Immunopharma is followed within the immunology universe for its exposure to chronic-disease treatment demand and catalyst-driven clinical updates., Biotechnology.
What is Lyell?
Lyell Immunopharma is an immunology-oriented biopharmaceutical company focused on inflammatory and immune-mediated disease programs, where each new data point can reshape expectations for the pipeline and the next catalyst window.
Which conditions is Lyell Immunopharma targeting with Lyell?
Lyell Immunopharma is associated with immunology based on its company overview and current catalyst commentary.
What is Immunopharma?
Lyell Immunopharma is an immunology-oriented biopharmaceutical company focused on inflammatory and immune-mediated disease programs, where each new data point can reshape expectations for the pipeline and the next catalyst window.